Compare Novartis with SURANA STRIP - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs P.M. TELELINNKS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS P.M. TELELINNKS NOVARTIS/
P.M. TELELINNKS
 
P/E (TTM) x 84.7 -352.0 - View Chart
P/BV x 2.6 0.9 283.8% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 NOVARTIS   P.M. TELELINNKS
EQUITY SHARE DATA
    NOVARTIS
Mar-21
P.M. TELELINNKS
Mar-21
NOVARTIS/
P.M. TELELINNKS
5-Yr Chart
Click to enlarge
High Rs7705 16,075.2%   
Low Rs5012 32,532.5%   
Sales per share (Unadj.) Rs154.514.5 1,065.9%  
Earnings per share (Unadj.) Rs8.50 17,776.4%  
Cash flow per share (Unadj.) Rs13.40 27,545.2%  
Dividends per share (Unadj.) Rs10.000-  
Avg Dividend yield %1.60-  
Book value per share (Unadj.) Rs289.26.4 4,536.4%  
Shares outstanding (eoy) m24.6910.08 244.9%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x4.10.2 1,884.9%   
Avg P/E ratio x75.166.4 113.0%  
P/CF ratio (eoy) x47.565.7 72.2%  
Price / Book Value ratio x2.20.5 442.8%  
Dividend payout %118.10-   
Avg Mkt Cap Rs m15,69132 49,207.4%   
No. of employees `000NANA-   
Total wages/salary Rs m1,0851 127,658.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,814146 2,610.7%  
Other income Rs m3320-   
Total revenues Rs m4,146146 2,838.0%   
Gross profit Rs m2671 31,023.3%  
Depreciation Rs m1220-   
Interest Rs m770-   
Profit before tax Rs m4001 47,105.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1910 51,729.7%   
Profit after tax Rs m2090 43,541.7%  
Gross profit margin %7.00.6 1,186.9%  
Effective tax rate %47.843.7 109.3%   
Net profit margin %5.50.3 1,664.7%  
BALANCE SHEET DATA
Current assets Rs m9,22442 21,919.0%   
Current liabilities Rs m3,5731 687,038.5%   
Net working cap to sales %148.228.4 520.9%  
Current ratio x2.680.9 3.2%  
Inventory Days Days1760-  
Debtors Days Days3719,180 0.2%  
Net fixed assets Rs m2,48021 11,763.8%   
Share capital Rs m123101 122.5%   
"Free" reserves Rs m7,018-36 -19,237.9%   
Net worth Rs m7,14164 11,111.6%   
Long term debt Rs m00-   
Total assets Rs m11,70363 18,532.5%  
Interest coverage x6.2NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.32.3 14.1%   
Return on assets %2.40.8 318.4%  
Return on equity %2.90.7 391.1%  
Return on capital %6.71.3 501.7%  
Exports to sales %9.30-   
Imports to sales %00-   
Exports (fob) Rs m354NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3540-   
Fx outflow Rs m9740-   
Net fx Rs m-6210-   
CASH FLOW
From Operations Rs m-69219 -3,656.1%  
From Investments Rs m952NA-  
From Financial Activity Rs m-368NA-  
Net Cashflow Rs m-10919 -573.2%  

Share Holding

Indian Promoters % 0.0 47.2 -  
Foreign collaborators % 70.7 0.0 -  
Indian inst/Mut Fund % 0.8 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 29.3 52.8 55.6%  
Shareholders   45,141 3,413 1,322.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   NAVKETAN MERCHANTS  MAYUKH DEALTRADE  DHAN ROTO SP  WELLWORTH OVER  LAHOTI OVER.  



Today's Market

Sensex Trades Lower Tracking Weak Global Cues; IT & Energy Stocks Under Pressure(10:30 am)

Asian share markets are trading mostly lower today with lingering worries over a US rate hike partly offset by potentially positive news on the severity of the Omicron coronavirus variant.

Related Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for(Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology(Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Dec 6, 2021 02:56 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS